Healthcare [ 13/13 ] | Biotechnology [ 127/164 ]
NASDAQ | Common Stock
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States.
Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase II clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 for the treatment of primary sclerosing cholangitis, and GRI-0729, which are in pre-clinical development.
GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 7, 24 | -3.10 Increased by +41.79% | - |
| Feb 22, 24 | -3.10 Decreased by -2.49 K% | - |
| Nov 14, 23 | -0.52 Decreased by -475.67% | - |
| Aug 8, 23 | -19.53 Decreased by -9.67 K% | - |
| May 10, 23 | -5.33 Decreased by -2.32 K% | - |
| Feb 23, 23 | -0.12 Increased by +45.45% | -0.29 Increased by +58.62% |
| Nov 3, 22 | -0.09 Increased by +50.00% | -0.25 Increased by +64.00% |
| Jul 28, 22 | -0.20 Increased by +41.18% | -0.23 Increased by +13.04% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | N/A Decreased by N/A% | -1.89 M Increased by +22.76% | - - |
| Dec 31, 23 | 5.39 M Increased by +N/A% | -2.00 M Increased by +11.68% | Decreased by -37.15% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -2.14 M Decreased by -508.83% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -6.75 M Decreased by -2.19 K% | Decreased by N/A% - |
| Mar 31, 23 | 0.00 Decreased by N/A% | -2.44 M Increased by +7.32% | Decreased by N/A% - |
| Dec 31, 22 | 0.00 - | -2.27 M - | Decreased by N/A% - |
| Sep 30, 22 | 0.00 - | -351.00 K - | Decreased by N/A% - |
| Jun 30, 22 | N/A - | -295.00 K - | - - |